Guidance

Pharmaceutical price regulation scheme 2014

A 5-year voluntary scheme on the control of prices agreed between government and the Association of the British Pharmaceutical Industry (ABPI).

• From: Department of Health and Social Care
• Published: 3 December 2013
• Last updated: 22 January 2018
  Show all updates

  1. 22 January 2018

     Responsibility for administering Patient Access Schemes (PAS) now sits with NHS England instead of DHSC. Wording in chapter 5 updated to reflect this change.

  2. 21 December 2015

     Updated the addendum to the 2014 pharmaceutical price regulation scheme to clarify the way in which spending under the Cancer Drugs Fund is treated by the scheme.

  3. 21 August 2015

     Added document: Addendum to the 2014 pharmaceutical price regulation scheme and explanatory text.

  4. 3 December 2013

     First published.

Documents

The pharmaceutical price regulation scheme 2014

PDF, 794 KB, 135 pages

Addendum to the 2014 pharmaceutical price regulation scheme

PDF, 129 KB, 4 pages

Details

This document explains how the 2014 Pharmaceutical Price Regulation Scheme (PPRS) will provide assurance on the control of prices for the branded medicines bill for the NHS.

The scheme includes amendments by the ABPI and Department of Health to clarify the way in which spending under the Cancer Drugs Fund is treated by the scheme.

This document explains:

• status and membership of the scheme
• flexible pricing and patient access schemes
• PPRS payment mechanism
• levels of return and allowances
• dispute resolution

The 2014 PPRS is now superseded by the 2019 voluntary scheme for branded medicines pricing and access.